Nivolumab-related lichen planus of the lip in a patient with head and neck cancer.

[1]  M. Yılmaz,et al.  Nivolumab-induced lichen planus , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[2]  M. Alaibac,et al.  Linear bullous lichen planus associated with nivolumab , 2018, Clinical and experimental dermatology.

[3]  K. Harrington,et al.  Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. , 2018, Oral oncology.

[4]  V. Shi,et al.  Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature. , 2018, Dermatology online journal.

[5]  M. Dougan.  Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract , 2017, Front. Immunol..

[6]  R. Motzer,et al.  Oral lichenoid reactions associated with anti‐PD‐1/PD‐L1 therapies: clinicopathological findings , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  T. Honda,et al.  Lichen Planus in Irradiated Skin During Nivolumab Treatment. , 2017, Acta dermato-venereologica.

[8]  M. Tetzlaff,et al.  Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. , 2017, The American Journal of dermatopathology.

[9]  S. Gettinger,et al.  Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. , 2016, JAMA dermatology.

[10]  J. Utikal,et al.  Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. , 2016, European journal of cancer.

[11]  J. Weber.  Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. , 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.